Transcript Multipark focus

Multipark
Coordinator & Chair of Board
Professor Susanne Iwarsson
Assistant Coordinator & Deputy Chair of Board
Associate Professor Oskar Hansson
Multipark
Strategic research area
Advertised, applied for and evaluated by
means of traditional grant mechanisms
Transferred to the university in the annual
government budget proposition
Faculty funding – management decided by
the university & faculty
Multipark
2010 - 2014
110 MSEK funding for 5 years
(10, 16, 28, 28 and 28 MSEK)
3% Gothenburg University
5% Vice-chancellor, Lund
University
Multipark strategy
MISSION
Goal & Aims
The principal goal is to create a program that improves body
function and structure, as well as activity and participation, among
PD patients. In order to reach this goal, we aim to:
• Perform the first transplantation trial using stem cells
• Perform clinical trials using gene-transfer based therapy
• Perform clinical trials using small molecule based neuroprotective agents
• Implement accurate tools for estimation of the outcome of these
trials (e.g. wet biomarkers, improved rating-scales and bioimaging)
• Test the effects of evidence-based clinical interventions
Multipark focus
Board
Executive
group
Working groups
Board
Chair: Susanne Iwarsson*
Deputy Chair: Oskar Hansson*
Faculty management representative: Ingemar Carlstedt (?)
Anders Björklund
Elisabet Londos
Cecilia Lundberg*
Per Odin*
Roger Olsson*
Jens Schouenborg
PhD student representative: Hjalmar Bjartmarz
PhD student representative: Zuzanna Kurowska
* Executive Group
Education & Innovation
Director of Studies:
Associate professor Helena Jernström
Innovation Group:
Thomas Laurell, Roger Olsson, Tadeusz Wieloch
Infrastructure
Done so far
• Grant manager, information officer,
research & clinical administrators
• Director of Studies, 30%
• Infrastructure investments (two major
equipment, plus technical & statistics
resources)
• Travel grants
• Six 3rd year post-docs
Done so far
• Adjunct professor Roger Olsson & co-worker = Drug
Discovery Node
• Professorship in Chemical Biology and Drug
Discovery; one applicant under review
• Health Sciences Node established (postdoc, guest
researchers, PhD students, facilities)
• Professor Jan Lexell
• Professor Gunnar Gouras & co-worker
• Three junior group leaders with start-up packages (T.
Björklund, L. Roybon, M. Svanberg)
Done so far
• Clinical Sciences Node coming
• Visiting professor Paola Piccini
• Clinical Researcher, R. Smith – visiting
Hammersmith Hospital, London
• Professorship in Clinical Neuroscience
ratified by Faculty Board
• Four 50% clinical research positions
under review (16 applicants)
Economic Results
20
17.61
14.74
Millions
15
10
9.22
7.24
4.37
5
1.98
2010
Income
Expenses
2011
Accumulated capital at MedFak
2012
2013
2014
2015
2016
Management+joint activities
Infrastructure (evaluation 2013)
FoAss
Start-up Packages FoAss
Graduate School
Profs
Start-up Packages Prof
PhD students
Clinical Researchers
Postdocs
Other activities (i.e. innovation)
TOTAL costs (MSEK)
28.5
11.75
9.19
8.81
Available (MSEK)
1.5
17.97
18.34
15.40
2017
2012 and on
• Communication & active engagement
• Infrastructure and innovation
• Experimental Sciences Node – current
standing & future development
• Health Sciences, Clinical & Drug Discovery
Nodes – development intensified
• Strategic development, aiming for 2015 and
onwards